Introduction {#H1-1-ZLD190026}
============

Since antiretroviral therapy became widely available in the late 1990s, there has been a dramatic reduction in AIDS-related deaths due to opportunistic infections.^[@zld190026r1]^ The life expectancy of people living with HIV (PLWH) receiving antiretroviral therapy now approaches that of the general population, particularly for those with a CD4^+^ T-cell count within the normal range.^[@zld190026r2]^ Conversely, cancer has become a leading cause of morbidity and mortality in PLWH. From 1995 to 2009, cancer resulted in nearly two-fold as many deaths per 100 000 person-years in PLWH than in the general population (327 deaths per 100 000 person-years vs 186 deaths per 100 000 person-years).^[@zld190026r3]^ Non--AIDS-defining cancers represent 70% of these deaths and will increase with aging of the PLWH population.^[@zld190026r3]^

During the past decade, clinical trials of immune checkpoint inhibitors (ICIs) have changed the treatment landscape of many cancers. Historically, PLWH have been excluded from participation in oncology trials, which may affect generalizability of findings. In this systematic review and meta-analysis, we investigated characteristics of ICI trials associated with inclusion of PLWH.

Methods {#H1-2-ZLD190026}
=======

We performed a systematic search using the key word "checkpoint" to identify prospective trials involving programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) or cytotoxic T-lymphocyte--associated protein 4 ICIs published in 6 high-profile general medicine and oncology journals ([Table 1](#zld190026t1){ref-type="table"}) between January 1, 2016 and March 31, 2019. Two independent reviewers (D.V.A. and H.S.) assessed articles, including supplements and protocols, as well as ClinicalTrials.gov data to determine whether PLWH were eligible for enrollment. In cases of ambiguity, results were discussed with a third reviewer (D.H.). This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guideline.

###### Characteristics of Included Trials

  Characteristic                            Trials, No. (%) (N = 118)
  ----------------------------------------- ---------------------------
  Patients, No.                             306 093
  Mean (95% CI)                             260.1 (206.8-313.5)
  Median (interquartile range)              117.5 (51.5-403.5)
  Journal                                   
  *New England Journal of Medicine*         17 (14.4)
  *Lancet*                                  10 (8.5)
  *Lancet Oncology*                         37 (31.4)
  *Journal of Clinical Oncology*            37 (31.4)
  *JAMA*                                    1 (0.8)
  *JAMA Oncology*                           12 (10.1)
  *Annals of Oncology*                      4 (3.4)
  Publication date                          
  2016                                      27 (22.9)
  2017                                      36 (30.5)
  2018                                      38 (32.2)
  2019                                      17 (14.4)
  Involved PD-1 and PD-L1 ICIs              
  No                                        10 (8.5)
  Yes                                       108 (91.5)
  Combination of ICI with other treatment   
  No                                        74 (62.7)
  Yes                                       44 (37.3)
  Trial phase                               
  1                                         39 (33.1)
  2                                         50 (42.4)
  3                                         29 (24.6)
  Multicenter                               
  No                                        8 (6.8)
  Yes                                       110 (93.2)
  Tumor type                                
  Lung                                      24 (20.3)
  Melanoma                                  17 (14.4)
  Urothelial                                13 (11)
  Renal cell carcinoma                      8 (6.8)
  Head and neck squamous cell carcinoma     7 (5.9)
  Other                                     49 (41.5)
  Line of treatment                         
  First line metastatic                     40 (33.9)
  Other                                     78 (66.1)
  Patients with HIV allowed                 
  No                                        102 (95.3)
  Yes                                       5 (4.7)
  Missing                                   11
  Funding                                   
  Pharmaceutical industry                   98 (83.1)
  Academic                                  20 (16.9)

Abbreviations: ICI, immune checkpoint inhibitor; PD-1, programmed cell death 1; PD-L1, programmed-death ligand 1.

Logistic and linear regression were used to assess factors associated with inclusion of PLWH. We used the Peto odds ratio method for associations with 0-counts. *P* values were 2-tailed, and statistical significance was defined as *P* less than .05. No corrections were made for multiple significance testing. Data analysis was performed using SPSS statistical software version 25.0 (IBM) and Revmen review software version 5.3 (Cochrane) and conducted from June 1, 2019, to June 21, 2019.

Results {#H1-3-ZLD190026}
=======

Of 569 articles screened, 126 articles were trials of ICIs. We excluded 8 studies: 4 studies were duplicates, and 4 studies involved ICIs other than PD-1, PD-L1, or cytotoxic T-lymphocyte--associated protein 4. Our final analysis included 118 articles comprising 30 693 patients. Demographic data for the 118 articles are summarized in [Table 1](#zld190026t1){ref-type="table"}. For PLWH eligibility analysis, we excluded 11 trials owing to unavailability of data. Of 107 trials with PLWH inclusion criteria data, 5 trials (4.7%, 258 patients) allowed enrollment of PLWH. All 5 trials that allowed PLWH were academic, whereas no trials sponsored by a pharmaceutical company included PLWH (odds ratio, 259.77; 95% CI, 26.25-2570.61; *P* \< .001) ([Table 2](#zld190026t2){ref-type="table"}). Only phase 2 trials permitted PLWH entry; however, this is likely a confounder, as most academic trials were phase 2 (17 of 20 trials; 85%). No other factors were associated with PLWH inclusion.

###### Factors Associated With Inclusion of Patients with HIV in ICI Trials

  Factor                                    Trials, No.   OR (95% CI)   *P* Value                            
  ----------------------------------------- ------------- ------------- ----------- ------------------------ --------
  Funding                                                                                                    
  Pharmaceutical industry                   87            0             87          259.77 (26.25-2570.61)   \<.001
  Academic                                  15            5             20          1 \[Reference\]          
  Publication date                                                                                           
  2016                                      24            0             24          1 \[Reference\]          NA
  2017                                      29            1             30          0.16 (0.01-8.53)         .37
  2018                                      34            3             37          0.18 (0.02-1.91)         .16
  2019                                      15            1             16          0.08 (0.01-4.48)         .22
  Combination of ICI with other treatment                                                                    
  No                                        65            4             69          0.43 (0.04-4.07)         .47
  Yes                                       37            1             38          1 \[Reference\]          
  Involved PD-1 and PD-L1 ICIs                                                                               
  No                                        8             1             9           0.34 (0.03-3.42)         .36
  Yes                                       94            4             98          1 \[Reference\]          
  Tumor type                                                                                                 
  Lung                                      22            0             22          4.88 (0.58-40.74)        .14
  Melanoma                                  15            0             15          4.15 (0.41-41.39)        .22
  Urothelial                                13            0             13          3.96 (0.36-43.14)        .26
  Renal cell carcinoma                      7             0             7           3.45 (0.18-63.66)        .40
  Head and neck squamous cell carcinoma     6             1             7           0.58 (0.04-8.11)         .58
  Other                                     39            4             43          1 \[Reference\]          NA
  Line of treatment                                                                                          
  First line metastatic                     35            2             37          0.78 (0.12-4.91)         .80
  Other                                     67            3             70          1 \[Reference\]          
  Trial phase                                                                                                
  1                                         36            0             36          6.93 (1.13-42.24)        .04
  2                                         38            5             43          1 \[Reference\]          NA
  3                                         28            0             28          5.76 (0.90-36.53)        .06

Abbreviations: ICI, immune checkpoint inhibitors; NA, not applicable; PD-1, programmed cell death 1; PD-L1, programmed-death ligand 1; OR, odds ratio.

Discussion {#H1-4-ZLD190026}
==========

Limitations of our study include the lack of multivariable adjustment and absence of reporting the justification for PLWH exclusion. Nonetheless, our results demonstrate an almost universal exclusion of PLWH from trials involving ICIs. There are no good justifications for this practice. A 2019 systematic review^[@zld190026r4]^ demonstrated that the safety profile of PD-1 or PD-L1 ICIs in PLWH was similar to that of the general population, with no unusual adverse events. A study by Uldrick et al^[@zld190026r5]^ of a phase 1 trial involving 30 patients with HIV and advanced cancer treated with pembrolizumab reported a safety profile in keeping with studies of participants without HIV. While academic studies were more likely to allow PLWH, even within this group only 5 trials permitted PLWH. Whereas the reasons for PLWH exclusion are not disclosed in any protocols, we suspect that this practice results from dogma rather than reasoned decision.

A recent American Society of Clinical Oncology task force^[@zld190026r6]^ recommended inclusion of PLWH in oncology trials, particularly patients with T-cell CD4^+^ counts of 350 cells/μL or higher, who constitute a group with intact immunological function and survival in keeping with the general population. In contrast, the exclusion of PLWH is unsupported by current data, denies patients the benefit of ICI therapy, and is ethically unjustifiable. We advocate for a broader inclusion of these patients in oncology trials.
